Context Therapeutics - Manufacturing agreement with Lonza for CTIM-76

Context Therapeutics has signed a manufacturing agreement with Lonza to develop CTIM-76 (active ingredient and final product form), its bispecific antibody clinical candidate for claudin 6 (CLDN6)-positive cancers. The collaboration marks a crucial step required to progress CTIM-76 towards the clinic. As a reminder, in December 2022, Context announced the selection of CTIM-76 as its CLDN6 clinical candidate (co-developed with partner Integral Molecular) and is currently undertaking investigative new drug (IND)-enabling studies with the goal of submitting the IND application in Q124.